FibroGenesis to Present at LSX World Congress in London, UK

HOUSTON, TX / ACCESSWIRE / February 3, 2020 / FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced that Pete O’Heeron, FibroGenesis’s Chief Executive Officer and Tom Ichim, PhD, Chief Scientific Officer, will present at the LSX World Congress on Tuesday, February 4, 2020 at 11:45AM in London, UK.

In their presentation, Mr. O’Heeron and Dr. Ichim will discuss FibroGenesis’s chronic disease pipeline and the clinical benefits of using its proprietary fibroblast technology as a cell source to reverse these diseases. The company is preparing for continued clinical trials and development after receiving FDA clearance of its Investigational New Drug protocol.

About LSX World Congress

LSX World Congress brings together executives who will lead the future of healthcare and life science business strategy, investment, partnering, deal making and commercialization. LSX World Congress gathers the founders and CEOs of innovative start-ups which represent the breadth and depth of the cutting-edge research and technology driving the advances in the life science industry.

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 180 U.S. and international issued patents/patents pending issued across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit www.Fibro-Genesis.com.

Contact:
Clinical Contact: info@Fibro-Genesis.com

SOURCE: FibroGenesis

View source version on accesswire.com:
https://www.accesswire.com/574973/FibroGenesis-to-Present-at-LSX-World-Congress-in-London-UK

Staff

Recent Posts

CENTR Brands Corp. Appoints Director & New Chief Executive Officer

Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - CENTR Brands Corp. (CSE: CNTR) (FSE:…

11 hours ago

Haven Health Care Announces Achievement of Expansion

BOCA RATON, FL / ACCESSWIRE / March 28, 2024 / Haven Health Care Services, a…

12 hours ago

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global…

15 hours ago

LFTD Partners Inc. to Host Fourth Quarter and Full Year 2023 Earnings Conference Call on April 1, 2024

JACKSONVILLE, FL / ACCESSWIRE / March 28, 2024 / LFTD Partners Inc. ("LFTD Partners" or…

15 hours ago

Unify Medical Announces Todd Rasmussen, MD, as Special Consultant for Its Military Initiatives

Unify Medical, Inc., a privately held, smart surgical visualization technology company, announced the appointment of…

18 hours ago

Empathic Podiatry Selects eClinicalWorks Cloud EHR, Revenue Cycle Management and Robotic Process Automation to Improve Efficiency

Texas-based specialty practice chooses eClinicalWorks Cloud EHR to increase automation, streamline workflows, and enhance patient…

21 hours ago